SM
IMUC

Sabby Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Sabby Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-139,912
Closed -$445K – 300
2017
Q1 		$445K Sell
139,912
-20,217
-13% -$52.8K 0.02% 185
2016
Q4 		$328K Sell
160,129
-2
-0% -$6 0.02% 224
2016
Q3 		$756K Buy
160,131
+48,828
+44% +$314K 0.03% 204
2016
Q2 		$1.02M Buy
111,303
+1,019
+0.9% +$10.5K 0.05% 157
2016
Q1 		$1.28M Sell
110,284
-814
-0.7% -$9.16K 0.06% 139
2015
Q4 		$1.58M Buy
111,098
+6,867
+7% +$113K 0.09% 148
2015
Q3 		$1.75M Sell
104,231
-42,564
-29% -$775K 0.07% 173
2015
Q2 		$2.77M Sell
146,795
-431
-0.3% -$8.29K 0.1% 136
2015
Q1 		$2.86M Buy
+147,226
New +$3.7M 0.12% 115
2014
Q1 		– Sell
-625
Closed -$30.6K – 319
2013
Q4 		$23K Buy
+625
New +$59.2K ﹤0.01% 215

Other funds holding IMUC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sabby Management's IMUC Position: Q2 2017 in Review

Sabby Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2017, closing a stake of 139,912 shares — an estimated $445K sold.

Sabby Management first reported a position in IMUC in Q4 2013 and held it in 10 quarters. The position peaked at $2.86M in Q1 2015. 16 funds tracked by Wall St. Rank hold IMUC as of Q2 2017.

  • Sabby Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 139,912 ImmunoCellular Therapeutics, Ltd. shares in Q2 2017, an estimated $445K.
  • Sabby Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2013 and held it in 10 quarters.
  • Sabby Management's ImmunoCellular Therapeutics, Ltd. position peaked at $2.86M in Q1 2015.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.